Published in PLoS One on July 29, 2015
Prevalence of multiple sclerosis in Latin America and its relationship with European migration. Mult Scler J Exp Transl Clin (2016) 0.82
Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Chin Med J (Engl) (2016) 0.79
Candidate SNP Markers of Gender-Biased Autoimmune Complications of Monogenic Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters. Front Immunol (2016) 0.76
Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep (2017) 0.75
Epidemiology of neuromyelitis optica in Latin America. Mult Scler J Exp Transl Clin (2017) 0.75
Differential diagnosis of multiple sclerosis in Latin America. Mult Scler J Exp Transl Clin (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Chronic relapsing inflammatory optic neuropathy (CRION). Brain (2003) 2.83
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Evidence for a two-stage disability progression in multiple sclerosis. Brain (2010) 2.63
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol (1993) 2.23
Multiple sclerosis in the Japanese population. Lancet Neurol (2003) 2.15
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol (2009) 1.88
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol (2008) 1.51
Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med (2006) 1.46
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol (2012) 1.40
MS and neuromyelitis optica in Martinique (French West Indies). Neurology (2001) 1.30
Epidemiologic contributions to multiple sclerosis: an overview. Neurology (1980) 1.28
Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol (2011) 1.27
Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol (2006) 1.26
The clinical course of multiple sclerosis. Handb Clin Neurol (2014) 1.24
Transverse Myelitis: pathogenesis, diagnosis and treatment. Front Biosci (2004) 1.23
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler (2009) 1.13
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol (2009) 1.10
Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol (2008) 1.08
Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler (2009) 1.05
European Charcot Foundation Lecture: the natural history of multiple sclerosis and gender. J Neurol Sci (2009) 1.02
Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry (2008) 1.00
The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol (2011) 0.98
Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. Pathophysiology (2010) 0.95
The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol (2013) 0.94
Multiple sclerosis care in Latin America. Neurology (2014) 0.94
Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler (2011) 0.91
Multiple sclerosis in Latin America. Neuroepidemiology (2005) 0.91
Genetics and natural history of multiple sclerosis. Semin Neurol (2008) 0.89
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One (2013) 0.89
A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol (2008) 0.89
Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry (2007) 0.86
[Descriptive epidemiology of neuromyelitis optica in the Caribbean basin]. Rev Neurol (Paris) (2009) 0.85
Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci (2012) 0.85
Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler (2009) 0.85
Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler (2009) 0.82
African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis. ISRN Neurol (2012) 0.82
Pediatric multiple sclerosis. J Child Neurol (2012) 0.82
Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients. Mult Scler (2010) 0.81
Anti-AQP(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. J Spinal Cord Med (2012) 0.81
The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project. Mult Scler (2013) 0.80
Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr (2013) 0.80
[LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. Rev Neurol (2012) 0.79
European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil. PLoS One (2013) 0.79